Ulixacaltamide - Praxis Precision Medicine
Alternative Names: PRAX-944; Ulixacaltamide-HCl; Z 944Latest Information Update: 09 Jul 2026
At a glance
- Originator Zalicus
- Developer Praxis Precision Medicines; Taro Pharmaceuticals USA
- Class Analgesics; Antiepileptic drugs; Benzamides; Piperidines; Small molecules
- Mechanism of Action T-type calcium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Essential tremor
- Phase II Epilepsy
- No development reported Pain
Most Recent Events
- 07 Jul 2026 Praxis Precision Medicines in-licenses electronically controlled transdermal drug delivery systems from Remagine Labs
- 07 Jul 2026 Early research in Essential tremor in USA (Transdermal, Patch)
- 14 Apr 2026 FDA assigns PDUFA action date of (29/01/2027) for ulixacaltamide HCl for Essential tremor